62 related articles for article (PubMed ID: 35233014)
1. SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests.
Kay GA; Owen SI; Giorgi E; Clark DJ; Williams CT; Menzies S; Cuevas LE; Davies BMO; Eckersley NM; Hughes GL; Kirwan DE; Krishna S; Patterson EI; Planche T; Staines HM; Adams ER
Sci Rep; 2022 Mar; 12(1):3351. PubMed ID: 35233014
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera.
Ha B; Jadhao S; Hussaini L; Gibson T; Stephens K; Salazar L; Ciric C; Taylor M; Rouphael N; Edupuganti S; Rostad CA; Tompkins SM; Anderson EJ; Anderson LJ
Microbiol Spectr; 2021 Oct; 9(2):e0045821. PubMed ID: 34494855
[TBL] [Abstract][Full Text] [Related]
3. Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay.
Mariën J; Ceulemans A; Michiels J; Heyndrickx L; Kerkhof K; Foque N; Widdowson MA; Mortgat L; Duysburgh E; Desombere I; Jansens H; Van Esbroeck M; Ariën KK
J Virol Methods; 2021 Feb; 288():114025. PubMed ID: 33227340
[TBL] [Abstract][Full Text] [Related]
4. Development of a high-sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva.
Faustini SE; Jossi SE; Perez-Toledo M; Shields AM; Allen JD; Watanabe Y; Newby ML; Cook A; Willcox CR; Salim M; Goodall M; Heaney JL; Marcial-Juarez E; Morley GL; Torlinska B; Wraith DC; Veenith TV; Harding S; Jolles S; Ponsford MJ; Plant T; Huissoon A; O'Shea MK; Willcox BE; Drayson MT; Crispin M; Cunningham AF; Richter AG
Immunology; 2021 Sep; 164(1):135-147. PubMed ID: 33932228
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the SARS-CoV-2 spike protein ELISA and the Abbott Architect SARS-CoV-2 IgG nucleocapsid protein assays for detection of antibodies.
Wadhwa A; Yin S; Freeman B; Hershow RB; Killerby M; Yousaf AR; Lester S; Mills L; Buono SA; Pomeroy M; Owusu D; Chu VT; Tate JE; Bhattacharyya S; Hall P; Thornburg NJ; Kirking HL
PLoS One; 2021; 16(7):e0255208. PubMed ID: 34324576
[TBL] [Abstract][Full Text] [Related]
6. Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina.
Ojeda DS; Gonzalez Lopez Ledesma MM; Pallarés HM; Costa Navarro GS; Sanchez L; Perazzi B; Villordo SM; Alvarez DE; ; Echavarria M; Oguntuyo KY; Stevens CS; Lee B; Carradori J; Caramelo JJ; Yanovsky MJ; Gamarnik AV
PLoS Pathog; 2021 Jan; 17(1):e1009161. PubMed ID: 33444413
[TBL] [Abstract][Full Text] [Related]
7. Analysis of IgM, IgA, and IgG isotype antibodies Directed against SARS-CoV-2 spike glycoprotein and ORF8 in the course of COVID-19.
Meinberger D; Koch M; Roth A; Hermes G; Stemler J; Cornely OA; Streichert T; Klatt AR
Sci Rep; 2021 Apr; 11(1):8920. PubMed ID: 33903660
[TBL] [Abstract][Full Text] [Related]
8. Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study.
Murrell I; Forde D; Zelek W; Tyson L; Chichester L; Palmer N; Jones R; Morgan BP; Moore C
PLoS One; 2021; 16(1):e0245382. PubMed ID: 33497420
[TBL] [Abstract][Full Text] [Related]
9. Development and Evaluation of Quantitative Immunoglobulin G Enzyme-Linked Immunosorbent Assay for the Diagnosis of Coronavirus Disease 2019 Using Truncated Recombinant Nucleocapsid Protein as Assay Antigen.
Mutantu PN; Ngwe Tun MM; Nabeshima T; Yu F; Mukadi PK; Tanaka T; Tashiro M; Fujita A; Kanie N; Oshiro R; Takazono T; Imamura Y; Hirayama T; Moi ML; Inoue S; Izumikawa K; Yasuda J; Morita K
Int J Environ Res Public Health; 2021 Sep; 18(18):. PubMed ID: 34574555
[TBL] [Abstract][Full Text] [Related]
10. Development of ELISA-Based Assay for Detection of SARS-CoV-2 Neutralizing Antibody.
Mishra KP; Singh M; Saraswat D; Singh S
Viral Immunol; 2023 Oct; 36(8):495-502. PubMed ID: 37643285
[TBL] [Abstract][Full Text] [Related]
11. Performance estimation of two in-house ELISA assays for COVID-19 surveillance through the combined detection of anti-SARS-CoV-2 IgA, IgM, and IgG immunoglobulin isotypes.
Ramírez-Reveco A; Velásquez G; Aros C; Navarrete G; Villarroel-Espíndola F; Navarrete M; Fica A; Plaza A; Castro N; Verdugo C; Acosta-Jamett G; Verdugo CC
PLoS One; 2023; 18(2):e0270388. PubMed ID: 36745590
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 antibody responses associate with sex, age and disease severity in previously uninfected people admitted to hospital with COVID-19: An ISARIC4C prospective study.
Parker E; Thomas J; Roper KJ; Ijaz S; Edwards T; Marchesin F; Katsanovskaja K; Lett L; Jones C; Hardwick HE; Davis C; Vink E; McDonald SE; Moore SC; Dicks S; Jegatheesan K; Cook NJ; Hope J; Cherepanov P; McClure MO; Baillie JK; Openshaw PJM; Turtle L; Ho A; Semple MG; Paxton WA; Tedder RS; Pollakis G;
Front Immunol; 2023; 14():1146702. PubMed ID: 37056776
[TBL] [Abstract][Full Text] [Related]
13. The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients.
Luo H; Jia T; Chen J; Zeng S; Qiu Z; Wu S; Li X; Lei Y; Wang X; Wu W; Zhang R; Zou X; Feng T; Ding R; Zhang Y; Chen YQ; Sun C; Wang T; Fang S; Shu Y
Front Immunol; 2021; 12():632814. PubMed ID: 33763078
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of SARS-CoV-2 IgG antibodies and neutralising antibodies in rheumatic and musculoskeletal diseases patients with COVID-19.
Wang Q; Wu Y; Wu L; Lu C; Ke Y; Wang Y; Gu L; Shen Y; Tan W
Clin Exp Rheumatol; 2024 May; 42(5):1035-1042. PubMed ID: 38372719
[TBL] [Abstract][Full Text] [Related]
15. Development of a cost-effective quantitative in-house ELISA assay for screening anti-S1 IgG antibodies targeting SARS-CoV-2.
Al-Saeedi AS; Abdulamir AS; Alubaidi GT
J Med Life; 2023 Jun; 16(6):883-889. PubMed ID: 37675173
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometry detection of sustained humoral immune response (IgG + IgA) against native spike glycoprotein in asymptomatic/mild SARS-CoV-2 infection.
Piñero P; Marco De La Calle FM; Horndler L; Alarcón B; Uribe Barrientos M; Sarmiento H; Tarín F
Sci Rep; 2021 May; 11(1):10716. PubMed ID: 34021205
[TBL] [Abstract][Full Text] [Related]
17. Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.
Adetifa IMO; Uyoga S; Gitonga JN; Mugo D; Otiende M; Nyagwange J; Karanja HK; Tuju J; Wanjiku P; Aman R; Mwangangi M; Amoth P; Kasera K; Ng'ang'a W; Rombo C; Yegon C; Kithi K; Odhiambo E; Rotich T; Orgut I; Kihara S; Bottomley C; Kagucia EW; Gallagher KE; Etyang A; Voller S; Lambe T; Wright D; Barasa E; Tsofa B; Bejon P; Ochola-Oyier LI; Agweyu A; Scott JAG; Warimwe GM
Nat Commun; 2021 Jun; 12(1):3966. PubMed ID: 34172732
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay.
Papenburg J; Cheng MP; Corsini R; Caya C; Mendoza E; Manguiat K; Lindsay LR; Wood H; Drebot MA; Dibernardo A; Zaharatos G; Bazin R; Gasser R; Benlarbi M; Gendron-Lepage G; Beaudoin-Bussières G; Prévost J; Finzi A; Ndao M; Yansouni CP
Open Forum Infect Dis; 2021 Jun; 8(6):ofab220. PubMed ID: 34136587
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a SARS-CoV-2 lateral flow assay using the plaque reduction neutralization test.
Xie X; Nielsen MC; Muruato AE; Fontes-Garfias CR; Ren P
Diagn Microbiol Infect Dis; 2021 Feb; 99(2):115248. PubMed ID: 33130510
[TBL] [Abstract][Full Text] [Related]
20. Marked Increase in Avidity of SARS-CoV-2 Antibodies 7-8 Months After Infection Is Not Diminished in Old Age.
Pichler D; Baumgartner M; Kimpel J; Rössler A; Riepler L; Bates K; Fleischer V; von Laer D; Borena W; Würzner R
J Infect Dis; 2021 Sep; 224(5):764-770. PubMed ID: 34086960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
